According to Zhitong Financial App, Hanson Pharmaceuticals (03692.HK) announced that on December 16, 2025, Jiangsu Hausen Pharmaceutical Group Co., Ltd. (licensor), a wholly-owned subsidiary of the company, entered into an exclusive licensing, cooperation and distribution agreement (license agreement) with Glenmark Specialty S.A. (licensee) for ametinib. Ametinib is a triple-representative dermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) used to treat non-small cell lung cancer (NSCLC).

According to Zhitong Financial App, Hanson Pharmaceuticals (03692.HK) announced that on December 16, 2025, Jiangsu Hausen Pharmaceutical Group Co., Ltd. (licensor), a wholly-owned subsidiary of the company, entered into an exclusive licensing, cooperation and distribution agreement (license agreement) with Glenmark Specialty S.A. (licensee) for ametinib. Ametinib is a triple-representative dermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) used to treat non-small cell lung cancer (NSCLC).